ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Contract firms strike deals

June 14, 2004 | APPEARED IN VOLUME 82, ISSUE 24

Three fine chemicals companies have reached contract-manufacturing agreements with drug industry partners. In the small-molecule realm, Lonza will produce Isotechnika's trans-ISA247, an immunosuppressant, for use in upcoming clinical trials. In biopharmaceuticals, Biovitrum will manufacture Maxygen's improved form of interferon ß, a multiple sclerosis drug, for Phase I and II clinical trials. And also in biopharma, Akzo Nobel's Diosynth unit will make clinical quantities of a therapeutic monoclonal antibody for Human Genome Sciences.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment